Skip to main content
. Author manuscript; available in PMC: 2022 Dec 1.
Published in final edited form as: Transplant Cell Ther. 2021 Oct 2;27(12):993.e1–993.e8. doi: 10.1016/j.jtct.2021.08.031

Figure 2: Disease-free Survival and Overall Survival.

Figure 2:

A: Disease-free survival: The 1-year adjusted incidence of disease-free survival was 47% (95% CI 43-52%) after planned G-CSF and 58% (95% CI 53-63%) without G-CSF, p=0·0006

B: Overall survival: The 1-year adjusted incidence of overall survival was 61% (95% CI 56-65%) after planned G-CSF and 72% (95% CI 68-76%) without G-CSF, p=0·0001